- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Gail Bridges Explains the High Real-World Cure Rate for HCV
Real-world results for hepatitis C drugs have been very closely aligned to the clinical trial outcomes, which is likely due to a combination of factors, such as the effectiveness of the agents and better knowledge of using direct-acting antivirals, according to Gail Bridges, PharmD, of Accredo Health.
Real-world results for hepatitis C drugs have been very closely aligned to the clinical trial outcomes, which is likely due to a combination of factors, such as the effectiveness of the agents and better knowledge of using direct-acting antivirals, according to Gail Bridges, PharmD, of Accredo Health.
Transcript
How do the real-world results of the hepatitis C virus drugs Harvoni and Viekira Pak hold up to the results that were reported in the clinical trials?
Our data indicate that Accredo's patients achieve results that are right on point with the clinical trials. In our study patients achieved an average sustained viral response rate, which is really the clinical surrogate marker for cure, of 96%. And this was on par with the mid-90% range that each of these individual therapies described in their clinical trials.
Why do you think the real-world outcomes hold up so well to the clinical trial results?
I think a number of factors contribute to the successful results that we saw in our study. First, clearly these are very effective agents and we are becoming savvier as a medical community about use of the direct-acting antivirals. We have very robust guidelines to help us make smart choices, to help prescribers and plan sponsors match up patients with the regimen that most closely meets their specific needs. And, lastly, we placed a great deal of emphasis on adherence and education specific to hepatitis C, the drugs and the disease, to help these patients really succeed with these therapies.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Key Indicators of Myasthenia Gravis Disease Progression Reduced With Efgartigimod
April 18th 2025Research presented at the recent annual meeting of the Academy of Managed Care Pharmacy highlights outcomes among patients who have anti-acetylcholine receptor antibody-positive myasthenia gravis that include reduced exacerbations and need for immunoglobulin.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Bias Reduction, Better Access Key to COVID-19 Equity Gains
April 14th 2025Interventions that target enhancing health care equity among communities disproportionately affected by the COVID-19 pandemic can be improved by including comprehensive needs assessments at the patient, provider, and health system levels.
Read More
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More
